Skip to main content
SpringerLink
Log in

ARV costs high for implementing WHO 2013 ART guidelines

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

Reference

  • Onyekwena O, et al. Global Fund Cost Projections for Implementing WHO 2013 Guidelines. 22nd Conference on Retroviruses and Opportunistic Infections : (plus poster) abstr. 1114, 23 Feb 2015.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ARV costs high for implementing WHO 2013 ART guidelines. PharmacoEcon Outcomes News 725, 6 (2015). https://doi.org/10.1007/s40274-015-2020-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2020-2

Search

Navigation